Xencor, Inc Total Contract Liability
Xencor, Inc (XNCR) had Total Contract Liability of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability $0.00.
- 2026-03-31: Contract with Customer, Liability $0.00.
- 2025-12-31: Contract with Customer, Liability $0.00.
- 2025-06-30: Contract with Customer, Liability $0.00.
| Period end | Contract with Customer, Liability |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2023-03-31 | $30.10M 10-Q · filed 2023-05-08 |
| 2022-09-30 | $35.20M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $35.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $35.50M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $37.30M 10-K · filed 2022-02-24 |
| 2021-09-30 | $13.00M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $19.20M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $77.80M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $92.60M 10-K · filed 2022-02-24 |
| 2020-09-30 | $43.80M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $44.70M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $46.20M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $47.10M 10-K · filed 2021-02-24 |
| 2019-09-30 | $48.20M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $48.80M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $63.10M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $40.10M 10-K · filed 2020-02-25 |
| 2018-09-30 | $40.10M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $60.10M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $40.10M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |